Bio-Techne (NASDAQ:TECH) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS

Key Points

• Bio‑Techne reported Q3 adjusted EPS of $0.53 vs. $0.55 expected and revenue of $311.4M vs. ~$316M consensus, a ~1.5–2% year‑over‑year decline, and shares fell about $9.89 to $46.79 on heavy volume.
• Despite the miss, management highlighted improved profitability with a 34.2% adjusted operating margin and strong growth in key areas—Spatial Biology (COMET >65% growth) and GMP proteins (nearly 50% ex‑fast‑track)—plus a record backlog and first COMET installed in China.
• Company warned of near‑term demand headwinds from cuts to U.S. academic funding and weaker emerging‑biotech spending (about ~400 bps timing headwinds) but expects a meaningful recovery by fiscal 2027.

Bio-Techne (NASDAQ:TECH - Get Free Report) posted its earnings results on Wednesday. The biotechnology company reported $0.53 EPS for the quarter, missing the consensus estimate of $0.55 by ($0.02), FiscalAI reports. Bio-Techne had a net margin of 6.67% and a return on equity of 13.94%. The firm had revenue of $311.42 million during the quarter, compared to analyst estimates of $316.08 million. During the same period in the previous year, the company posted $0.56 EPS. Bio-Techne's revenue for the quarter was down 1.5% compared to the same quarter last year.

Here are the key takeaways from Bio-Techne's conference call:

• Company reported a 2% organic revenue decline in Q3 but improved profitability with adjusted operating margin of 34.2%; management says the quarter faced ~400 bps of timing headwinds and that underlying organic growth was +2% excluding those items.
• Spatial biology (COMET) delivered >65% growth with a record backlog and the first COMET installed in China, positioning the platform for continued expansion.
• Excluding two Fast Track cell therapy customers, the GMP protein portfolio grew nearly 50% year-over-year, and Bio‑Techne plans to acquire the remainder of Wilson Wolf (G‑Rex bioreactors) by end of 2027 to bolster cell therapy manufacturing exposure.
• Emerging biotech spending remains the largest downside risk — revenues were weak (high-single-digit decline) despite recent strong funding trends, which management says typically take 2–3 quarters to translate into customer spending and expects a meaningful recovery in fiscal 2027.

Bio-Techne Price Performance

NASDAQ TECH traded down $9.89 on Wednesday, hitting $46.79. 8,089,959 shares of the company's stock were exchanged, compared to its average volume of 2,383,219. The stock has a 50-day moving average of $54.70 and a 200-day moving average of $59.71. The company has a current ratio of 4.54, a quick ratio of 3.08 and a debt-to-equity ratio of 0.13. Bio-Techne has a 52 week low of $45.12 and a 52 week high of $72.16. The stock has a market cap of $7.32 billion, a price-to-earnings ratio of 91.91, a P/E/G ratio of 3.60 and a beta of 1.41.

Key Headlines Impacting Bio-Techne

Here are the key news stories impacting Bio-Techne this week:

• Positive Sentiment: Operating profitability improved (GAAP EPS rose year over year and management highlighted operating‑margin expansion), which supports near‑term earnings quality. Read More.
• Positive Sentiment: Several growth vectors performed well — large pharma (double‑digit growth), Spatial Biology (mid‑teens), Proteomic Analysis instruments (mid‑single digits) and GMP proteins (nearly 50% ex‑fast‑track) — which can support longer‑term revenue recovery. Read More.
• Positive Sentiment: The board declared a quarterly cash dividend of $0.08 per share, which is supportive for income‑oriented holders. Read More.
• Neutral Sentiment: Management explained the revenue miss as partly due to timing of large Commercial Supply shipments and a prior‑year tailwind from GMP fast‑track orders — an operational timing issue that may reverse in future quarters. Read More.
• Negative Sentiment: Revenue and adjusted EPS missed consensus: revenue $311.4M vs. ~$316M expected and adjusted EPS $0.53 vs. $0.55 expected; reported revenue declined ~2% year‑over‑year — the primary catalyst for the selloff. Read More.
• Negative Sentiment: Demand headwinds from cuts to U.S. academic funding and weaker emerging‑biotech spending were flagged as ongoing risks to near‑term growth. Read More.
• Negative Sentiment: Market reaction: shares fell sharply on the mixed print and below‑estimate top line, trading well above average volume — indicating investor concern about near‑term revenue outlook. Read More.

Institutional Investors Weigh In On Bio-Techne

Several institutional investors and hedge funds have recently added to or reduced their stakes in TECH. Measured Wealth Private Client Group LLC bought a new stake in Bio-Techne during the third quarter worth $32,000. iSAM Funds UK Ltd acquired a new position in shares of Bio-Techne during the third quarter worth $33,000. EverSource Wealth Advisors LLC increased its holdings in shares of Bio-Techne by 506.3% during the second quarter. EverSource Wealth Advisors LLC now owns 673 shares of the biotechnology company's stock worth $35,000 after buying an additional 562 shares in the last quarter. Los Angeles Capital Management LLC acquired a new position in shares of Bio-Techne during the fourth quarter worth $39,000. Finally, Itau Unibanco Holding S.A. increased its holdings in shares of Bio-Techne by 81.5% during the fourth quarter. Itau Unibanco Holding S.A. now owns 1,009 shares of the biotechnology company's stock worth $59,000 after buying an additional 453 shares in the last quarter. 98.95% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. Wells Fargo & Company boosted their price target on Bio-Techne from $70.00 to $76.00 and gave the company an "overweight" rating in a research note on Friday, February 6th. Weiss Ratings cut Bio-Techne from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Friday, March 27th. Stifel Nicolaus set a $65.00 price target on Bio-Techne and gave the company a "hold" rating in a research note on Thursday, February 5th. Citigroup reiterated a "buy" rating and issued a $80.00 price target (up from $70.00) on shares of Bio-Techne in a research note on Wednesday, February 4th. Finally, Zacks Research upgraded Bio-Techne from a "strong sell" rating to a "hold" rating in a research note on Monday, February 9th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Bio-Techne presently has an average rating of "Moderate Buy" and a consensus price target of $72.77.

About Bio-Techne

Bio-Techne Corporation NASDAQ: TECH is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.

Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.